Skip to main content

Table 2 Baseline characteristics of study patients

From: The impact of cytochrome 450 and Paraoxonase polymorphisms on clopidogrel resistance and major adverse cardiac events in coronary heart disease patients after percutaneous coronary intervention

ParametersTotal
(n = 160)
Non-responders (n = 40)Responders
(n = 120)
P
Age62.35 ± 12.7660.83 ± 11.4762.86 ± 13.170.385
Male/Female(n/n)121/3931/990/300.834
BMI24.03 ± 3.0624.09 ± 3.4724.01 ± 2.920.881
Hypertension(%)108(67.5%)24(60%)84(70%)0.165
Diabetes(%)40(25%)17(42.5%)23(19.17%)0.003*
smoking(%)62(38.75%)21(52.5%)41(34.17%)0.039*
Dyslipidemia(%)148(92.5%)36(92.31%)112(93.33%)0.732
ACEI/ARB (%)81(50.63%)19(47.5%)62(51.67%)0.716
CCB(%)38(23.75%)9(22.5%)29(24.17%)0.508
Statin(%)152(95%)36(92.31%)116(96.67%)0.2
PPI (%)48(30%)14(35%)34(28.5%)0.272
Nitrates65(40.625%)18(45%)47(39.17%)0.515
β-receptor blocker148(92.5%)36(90%)112(93.33%)0.488
Diuretics22(13.75%)6(15%)16(13.33%)0.791
Rivaroxaban12 (7.5%)4(10%)8(6.67%)0.488
Panax Notoginseng14(8.75%)5(8%)9(7.5%)0.332
Metal stent14 (8.75%)3(7.5%)11(9.17%)0.747
Drug-eluting stent146(91.25%)37(92.5%)109(90.83%)0.747
Infarct artery LAD115(71.88%)29(72.5%)86(71.67%)0.919
Infarct artery LCX108(67.5%)24(60%)84(70%)0.242
Infarct artery RCA135(84.38%)34(85%)101(84.17%)0.9
Infarct artery LM35(21.88%)8(20%)27(22.5%)0.74
clinical presentation
Angina25(15.63%)6(15%)19(15.83%)0.9
AMI116(72.5%)27(67.5%)89(74.16%)0.413
  1. CCB Calcium channel blockers
  2. PPI Proton pump inhibitors
  3. ACEI/ARB angiotensin converting enzyme inhibitor/ angiotensin II receptor antagonist
  4. LAD left anterior descending artery
  5. LCX left circumflex artery
  6. RCA right coronary artery
  7. LM left main coronary artery
  8. AMI acute myocardial infarction
  9. *Variable is significant difference between responders and non-responders at p-value< 0.05